Restatement (Unaudited) - Consolidated Statements of Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2022	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating activities:
Net income (loss)	$ 40,644	$ (5,024)	$ (25,937)	$ (30,961)	$ 9,683	$ 4,432	$ (50,403)	$ 59,073
Adjustments to net income (loss):
Provision for (recovery of) bad debts			145	510	660	2,599	(467)	595
Deferred tax expense (benefit)			4,349	(23,910)	(36,002)	(31,565)	(10,102)	(2,739)
Depreciation and amortization			23,608	49,795	74,957	101,059	25,946	27,474
Amortization of debt discount and issuance costs			1,710	3,286	5,003	6,857	15,036	3,366
Equity-based compensation			4,508	7,472	11,677	14,982	13,757	4,809
Contingent consideration	(572)	(1,678)	(3,731)	(5,409)	(5,981)	(4,507)	2,696	26,441
Warranty provision			594	1,215	4,341	4,152	516	953
Provision for inventory obsolescence			409	409	(2,333)	(859)	990	1,225
Changes in operating assets and liabilities, net of acquisition
Accounts receivable			(44,268)	(106,548)	(139,036)	(76,984)	(116,848)	(23,038)
Inventories			(46,250)	(77,191)	(14,273)	20,870	(88,184)	28,340
Income tax receivables			(21,924)	(7,062)	(3,610)	5,611	8,106	(16,530)
Prepaid expenses and other			11,558	5,015	16,329	19,124	(21,226)	1,101
Accounts payable			59,551	74,645	42,205	12,667	7,015	(50,519)
Accounts payable - related party			(132)	(132)	(132)
Accrued expenses and other			7,027	3,356	41,271	1,024	9,133	10,913
Warranty payments					(373)
Income tax payable			(8,760)	(7,217)	2,951	(755)	(8,754)	6,870
Lease liabilities			6,085	4,700	1,914	3,784	221	0
Deferred revenue			(18,639)	47,263	34,772	59,002	(50,619)	(178,960)
Net cash provided by (used in) operating activities			(50,097)	(60,764)	44,023	141,493	(263,187)	(122,205)
Investing activities:
Purchase of property, plant and equipment			(2,357)	(3,895)	(6,690)	(10,619)	(3,357)	(1,338)
Acquisition of STI, net of cash acquired			(373,816)	(373,818)	(373,816)	(373,818)	0	0
Investment in equity security			0	0	0	0	(11,975)	0
Net cash used in investing activities			(376,173)	(377,713)	(380,506)	(384,437)	(15,332)	(1,338)
Financing activities:
Proceeds from Series A issuance			33,098	33,098	33,098	33,098	224,987	0
Proceeds from common stock issuance			15,885	15,885	15,885	15,885	120,645	145,532
Series A equity issuance costs			(175)	(575)	(1,167)	(1,893)	(7,195)	0
Common stock issuance costs			(450)	(450)	(450)	(450)	(3,873)	0
Dividends paid on Series A Preferred					(18,670)	(18,670)	(8,051)	0
Proceeds from revolving credit facility			52,000	101,000	116,000	116,000	126,033	0
Payments on revolving credit facility			0	(33,000)	(116,000)	(116,000)	(126,033)	(70)
Proceeds from issuance of other debt			6,229	30,599	39,219
Principal payments on other debt			(4,368)	(22,377)	(33,286)
Contingent consideration			(1,483)	(1,483)	(1,483)	(1,483)	(7,810)	0
Debt issuance costs			0	0		0	(6,590)	(36,011)
Net cash provided by (used in) financing activities			100,736	122,697	33,146	8,440	537,748	(129,273)
Effect of exchange rate changes on cash and cash equivalent balances			7,355	(844)	(1,555)	735	0	0
Net change in cash and cash equivalents			(318,179)	(316,624)	(304,892)	(233,769)	259,229	(252,816)
Cash and cash equivalents, beginning of period	51,046	49,491	367,670	367,670	367,670	367,670	108,441	361,257
Cash and cash equivalents, end of period	62,778	51,046	49,491	51,046	62,778	133,901	367,670	108,441
Supplemental Cash Flow Information
Stock consideration paid for acquisition of STI			200,224	200,224	200,224	200,224	0	$ 0
As Previously Reported
Operating activities:
Net income (loss)	40,822	(5,226)	(22,054)	(27,280)	13,542
Adjustments to net income (loss):
Provision for (recovery of) bad debts			145	510	660
Deferred tax expense (benefit)			6,649	(19,984)	(30,928)
Depreciation and amortization			23,023	47,579	71,207
Amortization of debt discount and issuance costs			1,710	3,286	5,003
Equity-based compensation			4,508	7,472	11,677
Contingent consideration	(572)	(1,678)	(3,731)	(5,409)	(5,981)
Warranty provision			594	1,215	4,341
Provision for inventory obsolescence			409	409	(2,333)
Changes in operating assets and liabilities, net of acquisition
Accounts receivable			(44,268)	(106,548)	(139,036)
Inventories			(46,250)	(77,191)	(14,273)
Income tax receivables			(21,924)	(7,062)	(3,610)
Prepaid expenses and other			5,960	(376)	11,146
Accounts payable			59,551	74,645	42,205
Accounts payable - related party			(132)	(132)	(132)
Accrued expenses and other			7,027	3,356	41,271
Warranty payments					(373)
Income tax payable			(8,760)	(7,217)	2,951
Lease liabilities			6,085	4,700	1,914
Deferred revenue			(18,639)	47,263	34,772
Net cash provided by (used in) operating activities			(50,097)	(60,764)	44,023
Investing activities:
Purchase of property, plant and equipment			(2,357)	(3,895)	(6,690)
Acquisition of STI, net of cash acquired			(373,816)	(373,818)	(373,816)
Investment in equity security			0	0	0
Net cash used in investing activities			(376,173)	(377,713)	(380,506)
Financing activities:
Proceeds from Series A issuance			33,098	33,098	33,098
Proceeds from common stock issuance			15,885	15,885	15,885
Series A equity issuance costs			(175)	(575)	(1,167)
Common stock issuance costs			(450)	(450)	(450)
Dividends paid on Series A Preferred					(18,670)
Proceeds from revolving credit facility			52,000	101,000	116,000
Payments on revolving credit facility			0	(33,000)	(116,000)
Proceeds from issuance of other debt			6,229	30,599	39,219
Principal payments on other debt			(4,368)	(22,377)	(33,286)
Contingent consideration			(1,483)	(1,483)	(1,483)
Debt issuance costs			0	0
Net cash provided by (used in) financing activities			100,736	122,697	33,146
Effect of exchange rate changes on cash and cash equivalent balances			7,355	(844)	(1,555)
Net change in cash and cash equivalents			(318,179)	(316,624)	(304,892)
Cash and cash equivalents, beginning of period	51,046	49,491	367,670	367,670	367,670	367,670
Cash and cash equivalents, end of period	62,778	51,046	49,491	51,046	62,778		367,670
Supplemental Cash Flow Information
Stock consideration paid for acquisition of STI			200,224	200,224	200,224
Restatement Adjustments
Operating activities:
Net income (loss)	(178)	202	(3,883)	(3,681)	(3,859)
Adjustments to net income (loss):
Provision for (recovery of) bad debts			0	0	0
Deferred tax expense (benefit)			(2,300)	(3,926)	(5,074)
Depreciation and amortization			585	2,216	3,750
Amortization of debt discount and issuance costs			0	0	0
Equity-based compensation			0	0	0
Contingent consideration	0	0	0	0	0
Warranty provision			0	0	0
Provision for inventory obsolescence			0	0	0
Changes in operating assets and liabilities, net of acquisition
Accounts receivable			0	0	0
Inventories			0	0	0
Income tax receivables			0	0	0
Prepaid expenses and other			5,598	5,391	5,183
Accounts payable			0	0	0
Accounts payable - related party			0	0	0
Accrued expenses and other			0	0	0
Warranty payments					0
Income tax payable			0	0	0
Lease liabilities			0	0	0
Deferred revenue			0	0	0
Net cash provided by (used in) operating activities			0	0	0
Investing activities:
Purchase of property, plant and equipment			0	0	0
Acquisition of STI, net of cash acquired			0	0	0
Investment in equity security			0	0	0
Net cash used in investing activities			0	0	0
Financing activities:
Proceeds from Series A issuance			0	0	0
Proceeds from common stock issuance			0	0	0
Series A equity issuance costs			0	0	0
Common stock issuance costs			0	0	0
Dividends paid on Series A Preferred					0
Proceeds from revolving credit facility			0	0	0
Payments on revolving credit facility			0	0	0
Proceeds from issuance of other debt			0	0	0
Principal payments on other debt			0	0	0
Contingent consideration			0	0	0
Debt issuance costs			0	0
Net cash provided by (used in) financing activities			0	0	0
Effect of exchange rate changes on cash and cash equivalent balances			0	0	0
Net change in cash and cash equivalents			0	0	0
Cash and cash equivalents, beginning of period	0	0
Cash and cash equivalents, end of period	$ 0	$ 0	0	0	0
Supplemental Cash Flow Information
Stock consideration paid for acquisition of STI			$ 0	$ 0	$ 0